tiprankstipranks
Trending News
More News >
JMDC Inc. (JP:4483)
:4483
Japanese Market
Advertisement

JMDC Inc. (4483) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4483

JMDC Inc.

(4483)

Rating:66Neutral
Price Target:
¥4,521.00
▲(6.85% Upside)
JMDC Inc. scores well due to its strong financial performance, characterized by consistent revenue growth and solid profitability margins. However, the high P/E ratio suggests potential overvaluation, and the technical indicators reflect a neutral market sentiment. The lack of earnings call data and corporate events limits further insights.

JMDC Inc. (4483) vs. iShares MSCI Japan ETF (EWJ)

JMDC Inc. Business Overview & Revenue Model

Company DescriptionJMDC Inc. provides medical statistics data services in Japan. The company operates through three segments: Healthcare-Big Data, Telemedicine, and Dispensing Pharmacy Support. It offers medical field big data services; life insurance field big data services; support services for health insurance associations and local government health services; health data platform; and medical institution support services. The company also provides remote image interpretation matching services and ASP services for remote image interpretation system; and develops and sells business systems for dispensing pharmacies. It serves health insurance unions, pharmaceutical companies, life and non-life insurance companies, research institutions, etc. The company was incorporated in 2002 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyJMDC Inc. generates revenue primarily through its data services and analytics platforms. The company collects and analyzes large volumes of medical and health-related data, which it then sells to clients in the healthcare industry, such as pharmaceutical companies, insurance firms, and healthcare providers. Revenue streams include subscription fees for access to their data platforms, customized data analytics services, and IT solutions that help clients improve healthcare outcomes and operational efficiencies. Significant partnerships with healthcare institutions and continuous innovation in data technology also contribute to the company's earnings.

JMDC Inc. Financial Statement Overview

Summary
JMDC Inc. exhibits strong financial performance with consistent revenue growth and solid profitability margins. The balance sheet is stable with manageable leverage, although the recent decline in free cash flow growth warrants attention.
Income Statement
85
Very Positive
JMDC Inc. demonstrates strong revenue growth with a TTM increase of 5.52%, supported by healthy gross and net profit margins of 57.16% and 17.43%, respectively. The EBIT and EBITDA margins are robust at 20.94% and 27.63%, indicating efficient operational management. The company has consistently grown its revenue over the years, showcasing a positive growth trajectory.
Balance Sheet
78
Positive
The balance sheet reflects a stable financial position with a moderate debt-to-equity ratio of 0.60, indicating manageable leverage. The return on equity is decent at 9.88%, suggesting effective use of equity to generate profits. The equity ratio stands at 52.23%, highlighting a solid equity base relative to total assets.
Cash Flow
70
Positive
Cash flow analysis reveals a decline in free cash flow growth by 17.14% in the TTM, which could be a concern. However, the operating cash flow to net income ratio is healthy at 1.62, and the free cash flow to net income ratio is strong at 85.57%, indicating good cash generation relative to profits.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue44.02B41.72B32.38B27.81B21.81B16.77B
Gross Profit24.65B23.85B19.25B15.86B12.59B9.62B
EBITDA12.06B11.53B9.23B7.98B6.51B4.88B
Net Income7.51B7.28B4.61B4.27B3.25B2.48B
Balance Sheet
Total Assets149.48B143.02B122.45B98.57B62.06B57.85B
Cash, Cash Equivalents and Short-Term Investments35.63B32.18B14.47B22.78B13.19B19.90B
Total Debt53.83B46.89B37.83B20.40B17.80B19.45B
Total Liabilities70.98B64.54B51.77B34.04B30.89B29.60B
Stockholders Equity78.05B78.02B70.59B64.54B31.18B28.25B
Cash Flow
Free Cash Flow10.41B12.57B-2.27B2.12B2.49B952.00M
Operating Cash Flow12.15B14.69B-17.00M4.06B3.81B3.18B
Investing Cash Flow-7.01B-3.47B-24.86B-22.77B-8.10B-9.08B
Financing Cash Flow12.62B6.48B16.58B28.30B-2.41B18.11B

JMDC Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4231.00
Price Trends
50DMA
4054.02
Positive
100DMA
3717.97
Positive
200DMA
3623.40
Positive
Market Momentum
MACD
45.23
Positive
RSI
57.31
Neutral
STOCH
57.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4483, the sentiment is Positive. The current price of 4231 is below the 20-day moving average (MA) of 4281.45, above the 50-day MA of 4054.02, and above the 200-day MA of 3623.40, indicating a neutral trend. The MACD of 45.23 indicates Positive momentum. The RSI at 57.31 is Neutral, neither overbought nor oversold. The STOCH value of 57.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4483.

JMDC Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
¥276.67B44.46
0.37%29.09%87.01%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
€298.04M15.7915.71%
€459.53M52.348.00%
79
Outperform
¥21.51B18.77
1.91%-6.29%-22.25%
73
Outperform
¥141.15B19.27
1.80%10.66%0.41%
43
Neutral
¥21.72B4,465.71
1.13%-0.58%-260.22%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4483
JMDC Inc.
4,279.00
-281.48
-6.17%
DE:EMO
EM Systems Co
4.36
1.21
38.41%
DE:3YV
Medley
14.20
-8.40
-37.17%
JP:2175
SMS Co., Ltd.
1,602.50
-495.09
-23.60%
JP:3649
FINDEX Inc.
836.00
-28.84
-3.33%
JP:3902
Medical Data Vision Co.Ltd.
597.00
81.00
15.70%

JMDC Inc. Corporate Events

JMDC Inc. Reports Strong Q1 2025 Financial Growth
Aug 6, 2025

JMDC Inc. reported significant financial growth for the first quarter ending June 30, 2025, with a 32.5% increase in revenue and a 48.8% rise in operating profit compared to the same period last year. This growth reflects the company’s strategic focus on its core operations after discontinuing its dispensing pharmacy support business, enhancing its market positioning and potentially increasing shareholder value.

JMDC Inc. Finalizes Share Subscription Rights for Employees and Directors
Jul 16, 2025

JMDC Inc. has finalized the details of share subscription rights to be issued to its directors, executive officers, and employees, as well as those of its subsidiaries. This move, decided in a board meeting on June 25, 2025, involves the issuance of 6,840 share subscription rights, allowing for the exercise of 684,000 common shares, potentially impacting the company’s equity structure and aligning employee interests with corporate growth.

JMDC Inc. Announces OMRON as New Parent Company
Jun 25, 2025

JMDC Inc. has announced that OMRON Corporation has become its new parent company after acquiring a majority stake through a tender offer. Despite this change, JMDC maintains operational independence with no business dependence on OMRON, ensuring protection for minority shareholders in any potential transactions.

JMDC Inc. Issues Share Subscription Rights to Boost Growth and Talent Retention
Jun 25, 2025

JMDC Inc. announced the issuance of share subscription rights to its directors, executive officers, and employees, as well as those of its subsidiaries, to enhance motivation and attract talent. This move is part of JMDC’s strategy to expand its business and achieve medium-term goals, ultimately enhancing corporate and shareholder value while maintaining reasonable share dilution.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025